ArticleClinical & translational immunology2019
The role and therapeutic implications of T cells in cancer of the lung.
Article in Clinical & translational immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Predicting Clinical Outcomes and Immunotherapy Responses in Lung Adenocarcinoma Based on Nicotine Response Characteristics.Current medicinal chemistry · 2026Article
- The transcription factor Blimp-1 is suppressed by SLAMF1 and drives Treg cell-mediated immune evasion in non-small cell lung cancer.BJC reports · 2025Article
- Spatial genomics reveals cholesterol metabolism as a key factor in colorectal cancer immunotherapy resistance.Frontiers in oncology · 2025Article
- Identification of a coagulation-related classification and signature that predict disease heterogeneity for colorectal cancer and pan-cancer patients.Frontiers in immunology · 2025Article
- Better together: biomimetic nanomedicines for high performance tumor therapy.Beilstein journal of nanotechnology · 2025Review
- Comprehensive Analysis of Lung Adenocarcinoma and Brain Metastasis through Integrated Single-Cell Transcriptomics.International journal of molecular sciences · 2024Article
- An inflammation-related subtype classification for analyzing tumor microenvironment and clinical prognosis in colorectal cancer.Frontiers in immunology · 2024Article
- Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer.NPJ precision oncology · 2023Article
- Telomerase deficiency and dysfunctional telomeres in the lung tumor microenvironment impair tumor progression in NSCLC mouse models and patient-derived xenografts.Cell death and differentiation · 2023Article
- Review
- IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression.Oncogene · 2022Article
- A Novel Prognostic Biomarker LPAR6 in Hepatocellular Carcinoma via Associating with Immune Infiltrates.Journal of clinical and translational hepatology · 2022Article
- Resveratrol analog, triacetylresveratrol, a potential immunomodulator of lung adenocarcinoma immunotherapy combination therapies.Frontiers in oncology · 2022Article
- Current Status of Fear of Disease Progression in Patients with Advanced Cancer and Usefulness of Dignity Therapy Intervention.Journal of healthcare engineering · 2022Article
- Markers of Immune Cell Exhaustion as Predictor of Survival in Surgically-Treated Early-Stage NSCLC.Frontiers in immunology · 2022Article
- Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used.Cancer immunology, immunotherapy : CII · 2021Article
- Lysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma.International journal of environmental research and public health · 2021Article
- Effect of selective lymph node dissection on immune function in patients with T1 stage non-small cell lung cancer: a randomized controlled trial.Translational cancer research · 2021Article
- Review
- Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?Theranostics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the leading cause of cancer-related death worldwide. The disease is classified into two major subtypes, small-cell lung cancer (SCLC) and the more prevalent non-small-cell lung cancer (NSCLC). First-line conventional therapies, such as chemotherapy, radiotherapy and surgery, have offered limited benefit, and patient prognosis remains poor with post-treatment recurrences representing a major cause of morbidity. Consequently, there is an urgent need for improved therapeutic options. Historically, NSCLC has been considered a non-immunogenic disease. However, increased understanding of tumor-immune interactions has challenged this paradigm in both lung and other malignancies, with cancer elimination by tumor-specific T cells increasingly well described in a myriad of solid tumors. Recent evidence has demonstrated that absent or weak anticancer responses are likely a product of tumor-derived immunosuppression. This knowledge, along with a greater appreciation for the role of T cells in lung cancer elimination, has driven development of novel immunotherapeutic approaches which are demonstrating remarkable clinical efficacy. This review examines the role of T cells in lung cancer, discussing the direction and clinical significance of current and future immunotherapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.